Tuesday, June 9, 2015

Federal Panel Weighs Approving Two New Cholesterol Drugs - alirocumab - evolocumab

Still going down the reduce cholesterol route rather than figure out the real cause of the problem. How to stop the inflammation that grabs the cholesterol floating by and packs it into plaque. Does no one understand cause and effect? Cholesterol is a secondary problem, we aren't even working on the primary problem.
http://www.nytimes.com/2015/06/10/health/cholesterol-levels-ldl-drugs-heart-attacks-fda-panel.html

No comments:

Post a Comment